{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T07:55:03Z","timestamp":1793174103626,"version":"4.5.0"},"reference-count":107,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jcehepatology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical and Experimental Hepatology"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1016\/j.jceh.2012.05.002","type":"journal-article","created":{"date-parts":[[2012,9,21]],"date-time":"2012-09-21T03:26:41Z","timestamp":1348198001000},"page":"247-259","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":141,"title":["An Update on Drug-induced Liver Injury"],"prefix":"10.1016","volume":"2","author":[{"given":"Harshad","family":"Devarbhavi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jceh.2012.05.002_bib1","first-page":"1","article-title":"International drug monitoring: the role of national centres. Report of a WHO meeting","volume":"498","year":"1972","journal-title":"WHO Tech Rep Ser"},{"key":"10.1016\/j.jceh.2012.05.002_bib2","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(00)02799-9","article-title":"Adverse drug reactions: definition, diagnosis and management","volume":"356","author":"Edwards","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.jceh.2012.05.002_bib3","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMra052270","article-title":"Drug-related hepatotoxicity","volume":"354","author":"Navarro","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jceh.2012.05.002_bib4","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/clpt.2011.63","article-title":"Drug safety sciences and the bottleneck in drug development","volume":"89","author":"Watkins","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jceh.2012.05.002_bib5","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/bmj.329.7456.15","article-title":"Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients","volume":"329","author":"Pirmohamed","year":"2004","journal-title":"BMJ"},{"key":"10.1016\/j.jceh.2012.05.002_bib6","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s00228-004-0888-z","article-title":"Incidence of drug-induced liver injury in medical inpatients","volume":"61","author":"Meier","year":"2005","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jceh.2012.05.002_bib7","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1111\/j.1365-2036.2006.03117.x","article-title":"Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic","volume":"24","author":"De Valle","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jceh.2012.05.002_bib8","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1053\/jhep.2002.34857","article-title":"Incidence of drug-induced hepatic injuries: a French population-based study","volume":"36","author":"Sgro","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2012.05.002_bib9","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1038\/ajg.2010.287","article-title":"Single-center experience with drug-induced liver injury from India: causes, outcome, prognosis, and predictors of mortality","volume":"105","author":"Devarbhavi","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jceh.2012.05.002_bib10","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1572-0241.2006.01019.x","article-title":"Etiology of new-onset jaundice: how often is it caused by idiosyncratic drug-induced liver injury in the United States?","volume":"102","author":"Vuppalanchi","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jceh.2012.05.002_bib11","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/01.meg.0000250581.77865.68","article-title":"Antibiotic therapy: a major cause of drug-induced jaundice in southwest England","volume":"19","author":"Hussaini","year":"2007","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2012.05.002_bib12","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1002\/hep.20948","article-title":"Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study","volume":"42","author":"Larson","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2012.05.002_bib13","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1002\/hep.23937","article-title":"Drug-induced acute liver failure: results of a U.S. multicenter, prospective study","volume":"52","author":"Reuben","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2012.05.002_bib14","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1002\/hep.23534","article-title":"Antituberculosis therapy-induced acute liver failure: magnitude, profile, prognosis, and predictors of outcome","volume":"51","author":"Kumar","year":"2010","journal-title":"Hepatology"},{"issue":"suppl 1","key":"10.1016\/j.jceh.2012.05.002_bib15","first-page":"A116","article-title":"Fulminant hepatic failure: cause, course and predictors of outcome","volume":"24","author":"Devarbhavi","year":"2005","journal-title":"Ind J Gastroenterol"},{"key":"10.1016\/j.jceh.2012.05.002_bib16","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1002\/hep.24527","article-title":"Drug-Induced liver injury with hypersensitivity features has a better outcome: a single-center experience of 39 children and adolescents","volume":"54","author":"Devarbhavi","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2012.05.002_bib17","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1002\/hep.23805","article-title":"Antituberculosis therapy drug-induced liver injury and acute liver failure","volume":"52","author":"Devarbhavi","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2012.05.002_bib18","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.gastro.2005.05.006","article-title":"Spanish group for the study of drug-induced liver disease. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period","volume":"129","author":"Andrade","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jceh.2012.05.002_bib19","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1053\/j.gastro.2008.09.011","article-title":"Drug induced liver injury network (DILIN). Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States","volume":"135","author":"Chalasani","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jceh.2012.05.002_bib20","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/hep.20800","article-title":"Outcome and prognostic markers in sever drug-induced liver disease","volume":"42","author":"Bjornsson","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2012.05.002_bib21","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1872-034X.2008.00486.x","article-title":"Drug-induced liver injury in Japan: an analysis of 1676 cases between 1997 and 2006","volume":"39","author":"Takikawa","year":"2009","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jceh.2012.05.002_bib22","first-page":"272","article-title":"Criteria of DILI. Report of an international consensus meeting","volume":"11","author":"Benichou","year":"1990","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2012.05.002_bib23","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/0895-4356(93)90101-6","article-title":"Causality assessment of adverse reactions to drugs \u2013 I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries","volume":"46","author":"Danan","year":"1993","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.jceh.2012.05.002_bib24","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/hep.23696","article-title":"Standardization of nomenclature and causality in drug-induced liver injury: summary of a clinical research workshop","volume":"52","author":"Fontana","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2012.05.002_bib25","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1164\/rccm.200510-1666ST","article-title":"Hepatotoxicity of antituberculosis therapy subcommittee","volume":"174","author":"Saukkonen","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jceh.2012.05.002_bib26","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1136\/gut.2008.163675","article-title":"Diagnosis, management and prevention of drug-induced liver injury","volume":"58","author":"Verma","year":"2009","journal-title":"Gut"},{"key":"10.1016\/j.jceh.2012.05.002_bib27","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/clpt.2011.58","article-title":"Case definition and phenotype standardization in drug-induced liver injury","volume":"89","author":"Aithal","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jceh.2012.05.002_bib28","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/pds.1211","article-title":"Hy's law: predicting serious hepatotoxicity","volume":"15","author":"Temple","year":"2006","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jceh.2012.05.002_bib29","series-title":"Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals on the Liver","author":"Zimmerman","year":"1999"},{"key":"10.1016\/j.jceh.2012.05.002_bib30","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.cld.2007.06.003","article-title":"Causality assessment and drug-induced hepatotoxicity: promises and pitfalls","volume":"11","author":"Shapiro","year":"2007","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.jceh.2012.05.002_bib31","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/clpt.2008.262","article-title":"Monitoring for hepatotoxicity: what is the predictive value of liver \u201cfunction\u201d tests?","volume":"85","author":"Senior","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jceh.2012.05.002_bib32","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.jhep.2008.10.021","article-title":"The long-term follow-up after idiosyncratic drug-induced liver injury with jaundice","volume":"50","author":"Bj\u00f6rnsson","year":"2009","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2012.05.002_bib33","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A\u00a0method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jceh.2012.05.002_bib34","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/hep.510260319","article-title":"Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis","volume":"26","author":"Maria","year":"1997","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2012.05.002_bib35","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1002\/hep.23577","article-title":"Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method","volume":"51","author":"Rockey","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2012.05.002_bib36","first-page":"64","article-title":"Role of acute viral hepatitis as a confounding factor in antituberculosis treatment induced hepatotoxicity","volume":"129","author":"Sarda","year":"2009","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.jceh.2012.05.002_bib37","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1053\/j.gastro.2011.07.051","article-title":"Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury","volume":"141","author":"Davern","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jceh.2012.05.002_bib38","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1053\/jhep.2001.20645","article-title":"Comparison of two clinical scales for causality assessment in hepatotoxicity","volume":"33","author":"Lucena","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2012.05.002_bib39","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nrgastro.2011.22","article-title":"Mechanisms of drug-induced liver injury: from bedside to bench","volume":"8","author":"Tujios","year":"2011","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2012.05.002_bib40","doi-asserted-by":"crossref","first-page":"E48","DOI":"10.1208\/aapsj080106","article-title":"Mechanisms of drug-induced liver injury","volume":"8","author":"Holt","year":"2006","journal-title":"AAPS J"},{"key":"10.1016\/j.jceh.2012.05.002_bib41","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2165\/00002018-200730040-00001","article-title":"Drug-induced liver injury","volume":"30","author":"Abboud","year":"2007","journal-title":"Drug Saf"},{"key":"10.1016\/j.jceh.2012.05.002_bib42","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1053\/gast.2001.20947","article-title":"Immunology of the healthy liver: old questions and new insights","volume":"120","author":"Mehal","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jceh.2012.05.002_bib43","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1111\/j.1365-2036.2007.03330.x","article-title":"The impact of eosinophilia and hepatic necrosis on prognosis in patients with drug-induced liver injury","volume":"25","author":"Bjornsson","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jceh.2012.05.002_bib44","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1146\/annurev.iy.12.040194.005015","article-title":"Tolerance, danger, and the extended family","volume":"12","author":"Matzinger","year":"1994","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jceh.2012.05.002_bib45","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nrd1750","article-title":"Idiosyncratic drug hepatotoxicity","volume":"4","author":"Kaplowitz","year":"2005","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jceh.2012.05.002_bib46","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/hep.510290241","article-title":"Repeat exposure to incremental doses of acetaminophen provides protection against acetaminophen-induced lethality in mice: an explanation for high acetaminophen dosage in humans without hepatic injury","volume":"29","author":"Shayiq","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2012.05.002_bib47","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1124\/pr.109.001727","article-title":"Inflammatory stress and idiosyncratic hepatotoxicity: hints from animal models","volume":"61","author":"Deng","year":"2009","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.jceh.2012.05.002_bib48","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/toxsci\/kfq168","article-title":"Idiosyncratic drug-induced liver injury and the role of inflammatory stress with an emphasis on an animal model of trovafloxacin hepatotoxicity","volume":"118","author":"Shaw","year":"2010","journal-title":"Toxicol Sci"},{"key":"10.1016\/j.jceh.2012.05.002_bib49","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1002\/hep.23588","article-title":"Drug-induced autoimmune hepatitis: clinical characteristics and prognosis","volume":"51","author":"Bj\u00f6rnsson","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2012.05.002_bib50","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/hep.24481","article-title":"The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury","volume":"54","author":"Suzuki","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2012.05.002_bib51","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0149-2918(00)90004-3","article-title":"Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity","volume":"22","author":"Kakuda","year":"2000","journal-title":"Clin Ther"},{"key":"10.1016\/j.jceh.2012.05.002_bib52","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1080\/15563650902752376","article-title":"Carnitine in the treatment of valproic acid-induced toxicity","volume":"47","author":"Lheureux","year":"2009","journal-title":"Clin Toxicol (Phila)"},{"key":"10.1016\/j.jceh.2012.05.002_bib53","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S1089-3261(02)00011-9","article-title":"Drug hepatotoxicity","volume":"6","author":"Goodman","year":"2002","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.jceh.2012.05.002_bib54","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1021\/tx0002435","article-title":"Indirect cytotoxicity of flucloxacillin toward human biliary epithelium","volume":"14","author":"Lakehal","year":"2001","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.jceh.2012.05.002_bib55","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1021\/tx0002029","article-title":"Identification of reactive metabolite of terbinafine","volume":"14","author":"Iverson","year":"2001","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.jceh.2012.05.002_bib56","series-title":"Drug-induced Cholestatic Liver Disease","author":"Kullack-Ublick","year":"2000"},{"key":"10.1016\/j.jceh.2012.05.002_bib57","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/hep.23720","article-title":"Pharmacogenetics of drug-induced liver injury","volume":"52","author":"Russman","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2012.05.002_bib58","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.pharmthera.2010.03.005","article-title":"Nuclear receptors as drug targets in cholestasis and drug-induced hepatotoxicity","volume":"126","author":"Zollner","year":"2010","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jceh.2012.05.002_bib59","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/MPG.0b013e31821d6cfd","article-title":"Characteristics of idiosyncratic drug-induced liver injury in children: results from the DILIN prospective study","volume":"53","author":"Molleston","year":"2011","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jceh.2012.05.002_bib60","first-page":"461","article-title":"Predisposing factors in hepatitis induced by isoniazid\u2013rifampin treatment of tuberculosis","volume":"118","author":"Gronhagen-Riska","year":"1978","journal-title":"Am Rev Resp Dis"},{"key":"10.1016\/j.jceh.2012.05.002_bib61","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2165\/00002018-200225020-00005","article-title":"Clinically significant interactions with drugs used in the treatment of tuberculosis","volume":"25","author":"Yew","year":"2002","journal-title":"Drug Saf"},{"key":"10.1016\/j.jceh.2012.05.002_bib62","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1056\/NEJM198211183072107","article-title":"Isoniazid-induced carbamazepine toxicity and vice versa: a double drug interaction","volume":"307","author":"Wright","year":"1982","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jceh.2012.05.002_bib63","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1164\/rccm.200206-626OC","article-title":"Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis","volume":"167","author":"Yee","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jceh.2012.05.002_bib64","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1128\/AAC.36.3.548","article-title":"Antagonism between isoniazid and the combination pyrazinamide\u2013rifampin against tuberculosis infection in mice","volume":"36","author":"Grosset","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jceh.2012.05.002_bib65","doi-asserted-by":"crossref","first-page":"640","DOI":"10.7326\/0003-4819-137-8-200210150-00007","article-title":"Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial","volume":"137","author":"Jasmer","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jceh.2012.05.002_bib66","first-page":"81","article-title":"Evaluation of risk factors for antituberculosis treatment induced hepatotoxicity","volume":"132","author":"Singla","year":"2010","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.jceh.2012.05.002_bib67","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1164\/rccm.2108091","article-title":"Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment","volume":"166","author":"Sharma","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jceh.2012.05.002_bib68","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.cld.2007.06.008","article-title":"Drug-induced liver injury associated with HIV medications","volume":"11","author":"Jain","year":"2007","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.jceh.2012.05.002_bib69","doi-asserted-by":"crossref","first-page":"S132","DOI":"10.1016\/j.jhep.2005.11.027","article-title":"Hepatotoxicity of antiretrovirals: incidence, mechanisms and management","volume":"44","author":"N\u00fa\u00f1ez","year":"2006","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2012.05.002_bib70","doi-asserted-by":"crossref","first-page":"e27810","DOI":"10.1371\/journal.pone.0027810","article-title":"Pharmacogenetic and pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients","volume":"6","author":"Yimer","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jceh.2012.05.002_bib71","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1056\/NEJMoa0706135","article-title":"HLA-B*5701 screening for hypersensitivity to abacavir","volume":"358","author":"Mallal","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jceh.2012.05.002_bib72","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jhep.2010.07.030","article-title":"The role of nucleoside and nucleotide analogues in nodular regenerative hyperplasia in HIV-infected patients: a case control study","volume":"54","author":"Cotte","year":"2011","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2012.05.002_bib73","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/hep.510310129","article-title":"Antituberculosis drug- related liver dysfunction in chronic hepatitis B","volume":"31","author":"Wong","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2012.05.002_bib74","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1001\/jama.283.1.74","article-title":"Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection","volume":"283","author":"Sulkowski","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.jceh.2012.05.002_bib75","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1097\/00002030-200012220-00011","article-title":"Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection","volume":"14","author":"den Brinker","year":"2000","journal-title":"AIDS"},{"key":"10.1016\/j.jceh.2012.05.002_bib76","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1440-1746.1997.tb00353.x","article-title":"A\u00a0prospective clinical study of isoniazid\u2013rifampicin\u2013pyrazinamide-induced liver injury in an area endemic for hepatitis B","volume":"12","author":"Hwang","year":"1997","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2012.05.002_bib77","first-page":"1304","article-title":"Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy","volume":"127","author":"Lee","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.jceh.2012.05.002_bib78","first-page":"448","article-title":"Risk factors of hepatitis during anti-tuberculous treatment and implications of hepatitis virus load","volume":"62","author":"Wang","year":"2011","journal-title":"J\u00a0Infect"},{"key":"10.1016\/j.jceh.2012.05.002_bib79","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1053\/jhep.2002.32102","article-title":"Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis","volume":"35","author":"Huang","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2012.05.002_bib80","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/j.1440-1746.2010.06355.x","article-title":"Role of polymorphic N-acetyl transferase2 and cytochrome P4502E1 gene in antituberculosis treatment-induced hepatitis","volume":"26","author":"Bose","year":"2011","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2012.05.002_bib81","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1046\/j.1440-1746.2001.02585.x","article-title":"Increased risk of antituberculosis drug-induced hepatotoxicity in individuals with glutathione S-transferase M1 \u2018null\u2019 mutation","volume":"16","author":"Roy","year":"2001","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2012.05.002_bib82","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00228-006-0111-5","article-title":"CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis","volume":"62","author":"Vuilleumier","year":"2006","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jceh.2012.05.002_bib83","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/j.1365-2710.2009.01101.x","article-title":"GSTT1 and GSTM1 gene deletions are not associated with hepatotoxicity caused by antitubercular drugs","volume":"35","author":"Chatterjee","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jceh.2012.05.002_bib84","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S0016-5085(99)70404-X","article-title":"HLA-association of amoxicillin\u2013clavulanate-induced hepatitis","volume":"117","author":"Hautekeete","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jceh.2012.05.002_bib85","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1002\/hep.20215","article-title":"HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease","volume":"39","author":"Andrade","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2012.05.002_bib86","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1053\/j.gastro.2011.04.001","article-title":"Susceptibility to amoxicillin\u2013clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles","volume":"141","author":"Lucena","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jceh.2012.05.002_bib87","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.jhep.2010.05.033","article-title":"Human leucocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury","volume":"53","author":"Donaldson","year":"2010","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2012.05.002_bib88","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/ng.379","article-title":"HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin","volume":"4","author":"Daly","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.jceh.2012.05.002_bib89","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1002\/hep.22272","article-title":"Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals","volume":"47","author":"Lammert","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2012.05.002_bib90","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/hep.23317","article-title":"Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events","volume":"51","author":"Lammert","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2012.05.002_bib91","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1002\/hep.24022","article-title":"Mitochondrial and immunoallergic injury increase risk of positive drug rechallenge after drug-induced liver injury: a systematic review","volume":"52","author":"Hunt","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2012.05.002_bib92","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1517\/14740330903397378","article-title":"Rechallenge in drug-induced liver injury: the attractive hazard","volume":"8","author":"Andrade","year":"2009","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jceh.2012.05.002_bib93","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2174\/157488606777934459","article-title":"Antiepileptic drug-induced hypersensitivity syndrome reactions","volume":"1","author":"Krivoy","year":"2006","journal-title":"Current Drug Safety"},{"key":"10.1016\/j.jceh.2012.05.002_bib94","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1086\/650576","article-title":"Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity","volume":"50","author":"Sharma","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jceh.2012.05.002_bib95","first-page":"65","article-title":"The management of anti-tuberculosis drug-induced hepatotoxicity","volume":"5","author":"Tahao\u00f0lu","year":"2001","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.jceh.2012.05.002_bib96","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S0190-9622(98)70508-0","article-title":"Methotrexate in psoriasis: consensus conference","volume":"38","author":"Roenigk","year":"1998","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jceh.2012.05.002_bib97","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1046\/j.1365-2036.2004.01819.x","article-title":"Monitoring methotrexate-induced hepatic fibrosis in patients with psoriasis: are serial liver biopsies justified?","volume":"19","author":"Aithal","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jceh.2012.05.002_bib98","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.jhep.2007.03.017","article-title":"Dangerous liaisons: drug, host and the environment","volume":"46","author":"Aithal","year":"2007","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2012.05.002_bib99","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.jhep.2007.01.024","article-title":"Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment","volume":"46","author":"Rosenberg","year":"2007","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2012.05.002_bib100","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1053\/j.gastro.2009.06.006","article-title":"Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure","volume":"137","author":"Lee","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jceh.2012.05.002_bib101","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1097\/MEG.0b013e32833aa11b","article-title":"Protective effect of N-acetylcysteine on antituberculosis drug-induced hepatotoxicity","volume":"22","author":"Baniasadi","year":"2010","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.jceh.2012.05.002_bib102","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1081\/CLT-120014646","article-title":"Treatment of amatoxin poisoning: 20-year retrospective analysis","volume":"40","author":"Enjalbert","year":"2002","journal-title":"J\u00a0Toxicol Clin Toxicol"},{"key":"10.1016\/j.jceh.2012.05.002_bib103","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1212\/WNL.56.10.1405","article-title":"Effect of l-carnitine treatment for valproate-induced hepatotoxicity","volume":"56","author":"Bohan","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.jceh.2012.05.002_bib104","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jhep.2009.11.012","article-title":"Liver disease associated with canalicular transport defects: current and future therapies","volume":"52","author":"Stapelbroek","year":"2010","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2012.05.002_bib105","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/01.mpg.0000178086.44155.73","article-title":"Vanishing bile duct syndrome: amoxicillin\u2013clavulanic acid associated intra-hepatic cholestasis responsive to ursodeoxycholic acid","volume":"41","author":"Smith","year":"2005","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jceh.2012.05.002_bib106","doi-asserted-by":"crossref","first-page":"345","DOI":"10.2165\/00002018-200427050-00006","article-title":"Leflunomide for the treatment of rheumatoid arthritis in clinical practice: incidence and severity of hepatotoxicity","volume":"27","author":"van Roon","year":"2004","journal-title":"Drug Saf"},{"key":"10.1016\/j.jceh.2012.05.002_bib107","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1345\/aph.1G345","article-title":"Steroid therapy for a case of severe drug-induced cholestasis","volume":"40","author":"Giannattasio","year":"2006","journal-title":"Ann Pharmacother"}],"container-title":["Journal of Clinical and Experimental Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0973688312000266?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0973688312000266?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T06:00:20Z","timestamp":1760853620000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0973688312000266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":107,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["S0973688312000266"],"URL":"https:\/\/doi.org\/10.1016\/j.jceh.2012.05.002","relation":{},"ISSN":["0973-6883"],"issn-type":[{"value":"0973-6883","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An Update on Drug-induced Liver Injury","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical and Experimental Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jceh.2012.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 INASL. Published by Elsevier, a division of Reed Elsevier India, Pvt. Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}